Synthesis and evaluation of novel pyrazolidinone analogs of PGE(2) as EP2 and EP4 receptors agonists
Department of Medicinal Chemistry, EMD-Serono Research Institute, Inc., Rockland, MA 02370, USA. Bioorganic & medicinal chemistry letters
(Impact Factor: 2.42).
01/2008; 17(23):6572-5. DOI: 10.1016/j.bmcl.2007.09.074
Replacement of the hydroxy cyclopentanone ring in PGE(2) with chemically more stable heterocyclic rings and substitution of the unsaturated alpha-alkenyl chain with a metabolically more stable phenethyl chain led to the development of potent and selective analogs of PGE(2). Compound 10f showed the highest potency and selectivity for EP(4) the receptor.
Available from: Mary Bebawy
- "Robust PGE 2 -type analogues have also been prepared through substitution of the native ring system with heterocycles. Thus, γ-lactam (Table 3, entries 6 and 9) (Elworthy et al., 2004; Cameron et al., 2006; Kambe et al., 2012) and pyrazolidinone (Zhao et al., 2007) systems have been used to improve chemical and metabolic stability and to produce analogues with higher EP receptor subtype selectivity. Stable analogues of PGE 3 , the COX-2/PGE synthase-derived product of ω−3 EPA biotransformation, could have value in anticancer drug development. "
[Show abstract] [Hide abstract]
ABSTRACT: Lipids have the potential for development as anticancer agents. Endogenous membrane lipids, such as ceramides and certain saturated fatty acids, have been found to modulate the viability of tumor cells. In addition, many tumors over-express cyclooxygenase, lipoxygenase or cytochrome P450 enzymes that mediate the biotransformation of ω-6 polyunsaturated fatty acids (PUFAs) to potent eicosanoid regulators of tumor cell proliferation and cell death. In contrast, several analogous products from the biotransformation of ω-3 PUFAs impair particular tumorigenic pathways. For example, the ω-3 17,18-epoxide of eicosapentaenoic acid activates anti-proliferative and proapoptotic signaling cascades in tumor cells and the lipoxygenase-derived resolvins are effective inhibitors of inflammatory pathways that may drive tumor expansion. However, the development of potential anti-cancer drugs based on these molecules is complex, with in vivo stability a major issue. Nevertheless, recent successes with the antitumor alkyl phospholipids, which are synthetic analogues of naturally-occurring membrane phospholipid esters, have provided the impetus for development of further molecules. The alkyl phospholipids have been tested against a range of cancers and show considerable activity against skin cancers and certain leukemias. Very recently, it has been shown that combination strategies, in which alkyl phospholipids are used in conjunction with established anticancer agents, are promising new therapeutic approaches. In future, the evaluation of new lipid-based molecules in single-agent and combination treatments may also be assessed. This could provide a range of important treatment options in the management of advanced and metastatic cancer.
Copyright © 2015. Published by Elsevier Inc.
Pharmacology [?] Therapeutics 01/2015; 150. DOI:10.1016/j.pharmthera.2015.01.008 · 9.72 Impact Factor
Annual reports in medicinal chemistry 01/2008; 43:293-309. DOI:10.1016/S0065-7743(08)00018-3 · 1.36 Impact Factor
[Show abstract] [Hide abstract]
ABSTRACT: Gamma-lactam analogs (2) of EP(4) receptor agonists were identified by substitution of the pyrazolidinone ring (1) with a pyrrolidinone ring. Several compounds (such as 2a, 2h) with high potency, selectivity and acceptable PK profiles were discovered. These were assessed in animal models of ovulation induction and bronchoconstriction.
Bioorganic & medicinal chemistry letters 02/2008; 18(2):821-4. DOI:10.1016/j.bmcl.2007.11.020 · 2.42 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.